Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | DAO | P14920 | 4/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.35 |
| ▸ | EPAS1 | Q99814 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.33 |
| ▸ | SMAD3 | P84022 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL70048 | 0.77 | NFKB1 (0.57) | KDM4EHPGDHSD17B10USP2HCAR2 | |
| SCHEMBL20894304 | 0.77 | HSD17B10 (0.38) | KDM4EHPGDHSD17B10USP2HCAR2 | |
| SCHEMBL1004764 | 0.75 | GAA (0.53) | KDM4EALDH1A1MAPTHIF1AEPAS1 | |
| SCHEMBL1787961 | 0.75 | NPC1 (0.44) | SMN1; SMN2ALDH1A1MAPTHIF1AEPAS1 | |
| Hydrochloric Acid SCHEMBL11595983 | 0.75 | NFKB1 (0.55) | KDM4EHPGDHSD17B10USP2HCAR2 | |
| SCHEMBL28802807 | 0.75 | NFKB1 (0.55) | KDM4EHPGDHSD17B10USP2HCAR2 | |
| SCHEMBL1309456 | 0.74 | — | — | |
| SCHEMBL4379866 | 0.74 | GLA (0.46) | KDM4EHPGDHSD17B10USP2HCAR2 | |
| SCHEMBL4379857 | 0.74 | GLA (0.46) | KDM4EHPGDHSD17B10USP2HCAR2 | |
| SCHEMBL13075694 | 0.72 | ALOX15 (0.65) | KDM4EHPGDHSD17B10HCAR2ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 148 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120040422-A | Indolone derivative containing triazole structure and preparation method and application thereof | 暨南大学附属顺德医院(佛山市顺德区第二人民医院、佛山市顺德区冯尧敬纪念医院) | 2025-05-27 | — | — | CN | disclosed |
| CN-117377665-A | PARP7 inhibitor and application thereof | 北京华森英诺生物科技有限公司 | 2024-01-09 | — | — | CN | disclosed |
| US-20230391752-A1 | PYRROLIDINE-3-CARBOXAMIDE DERIVATIVES AND RELATED USES | CHULALONGKORN UNIVERSITY (TH) | 2023-12-07 | — | — | US | disclosed |
| US-11731942-B1 | 3-substituted quinolin-2-one compounds as antibacterial agents | King Faisal University (SA) | 2023-08-22 | — | — | US | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-11421223-B2 | Processes and host cells for genome, pathway, and biomolecular engineering | ENEVOLV, INC. (US) | 2022-08-23 | — | — | US | disclosed |
| WO-2022087422-A9 | PYRROLIDINE-3-CARBOXAMIDE DERIVATIVES AND RELATED USES | CHULALONGKORN UNIVERSITY (TH) | 2022-06-09 | — | — | WO | disclosed |
| WO-2022087422-A1 | PYRROLIDINE-3-CARBOXAMIDE DERIVATIVES AND RELATED USES | CHULALONGKORN UNIVERSITY (TH) | 2022-04-28 | — | — | WO | disclosed |
| US-20190309289-A1 | PROCESSES AND HOST CELLS FOR GENOME, PATHWAY, AND BIOMOLECULAR ENGINEERING | ENEVOLV, INC. | 2019-10-10 | — | — | US | disclosed |
| EP-2488486-B1 | HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES | LIGAND PHARM INC (US) | 2019-08-14 | — | — | EP | disclosed |
| WO-2001046196-A1 | 4-SUBSTITUTED 7-AZA-INDOLIN-2-ONES AND THEIR USE AS PROTEIN KINASE INHIBITORS | SUGEN, INC. (US) | 2001-06-28 | — | — | WO | disclosed |
| WO-2001037820-A2 | IONIZABLE INDOLINONE DERIVATIVES AND THEIR USE AS PTK LIGANDS | SUGEN, INC. (US) | 2001-05-31 | — | — | WO | disclosed |
| US-6066639-A | ANTITUMOR AGENTS | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2000-05-23 | — | — | US | disclosed |
| EP-0354729-B1 | Cytotoxic drug conjugates | LILLY CO ELI (US) | 1994-01-12 | — | — | EP | disclosed |
| US-5144012-A | Antibody derivatized with a methotrexate drug | ELI LILLY AND COMPANY (US) | 1992-09-01 | — | — | US | disclosed |
| US-5094849-A | Antitumor | ELI LILLY AND COMPANY (US) | 1992-03-10 | — | — | US | disclosed |
| US-5028697-A | Antitumor agents, cell specific | ELI LILLY AND COMPANY (US) | 1991-07-02 | — | — | US | disclosed |
| US-5006652-A | Intermediates for antibody-vinca drug conjugates | ELI LILLY AND COMPANY (US) | 1991-04-09 | — | — | US | disclosed |
| EP-0354728-A2 | Cytotoxic drug conjugates | ELI LILLY AND COMPANY (US) | 1990-02-14 | — | — | EP | disclosed |
| EP-0354729-A2 | Cytotoxic drug conjugates | ELI LILLY AND COMPANY (US) | 1990-02-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230391752-A1 | PYRROLIDINE-3-CARBOXAMIDE DERIVATIVES AND RELATED USES | GLS2, PYGL, CPS1 | KDM4E 1778/4885HPGD 377/4885HSD17B10 1544/4885 |
| US-11731942-B1 | 3-substituted quinolin-2-one compounds as antibacterial agents | TOP2A, TOP1, POLB | KDM4E 2837/4885HPGD 1636/4885HSD17B10 2573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.